| [1]GREINACHER A.CLINICAL PRACTICE.Heparin-induced thrombocytopenia[J].N Engl J Med,2015,373(3):252-261.
[2]COSMI B.Current management of heparin-induced thrombocytopenia[J].Expert Rev Hematol,2015,8(6):837-849.
[3]BAROLETTI S,HURWITZ S,CONTI N A,et al.Thrombosis in suspected heparin-induced thrombocytopenia occurs more often with high antibody levels[J].Am J Med,2012,125(1):44-49.
[4]LASSILA R,ANTOVIC J P,ARMSTRONG E,et al.Practical viewpoints on the diagnosis and management of heparin-induced thrombocytopenia[J].Semin Thromb Hemost,2011,37(3):328-336.
[5]LAMURAGLIA G M,HOUBBALLAH R.The identification and management of heparin-induced thrombocytopenia in the vascular patient[J].J Vasc Surg,2012,55(2):562-570.
[6]MARTEL N,LEE J,WELLS P S.Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis:a meta-analysis[J].Blood,2005,106(8):2710-2715.
[7]KUTER D J.Thrombotic complications of central venous catheters in cancer patients[J].Oncologist,2004,9(2):207-216.
[8]WARKENTIN T E,SHEPPARD J A,SIGOUIN C S,et al.Gender imbalance and risk factor interactions in heparin-induced thrombocytopenia[J].Blood,2006,108(9):2937-2941.
[9]KELTON J G,WARKENTIN T E.Heparin-induced thrombocytopenia:a historical perspective[J].Blood,2008,112(7):2607-2616.
[10]BAKCHOUL T.An update on heparin-induced thrombocytopenia:diagnosis and management[J].Expert Opin Drug Saf,2016,15(6):787-797.
[11]GREINACHER A,FARNER B,KROLL H,et al.Clinical features of heparin-induced thrombocytopenia including risk factors for thrombosis.A retrospective analysis of 408 patients[J].Thrombosis Haemost,2005,94(1):132-135.
[12]KELTON J G,ARNOLD D M,BATES S M.Nonheparin anticoagulants for heparin-induced thrombocytopenia[J].N Engl J Med,2013,368(8):737-744.
[13]ALATRI A,ARMSTRONG A E,GREINACHER A,et al.Results of a consensus meeting on the use of argatroban in patients with heparin-induced thrombocytopenia requiring rntithrombotic therapy-a European Perspective[J].Thromb Res,2012,129(4):426-433.
[14]WARKENTIN T E.Ischemic limb gangrene with pulses[J].N Engl J Med,2015,373(24):2386-2388.
[15]SCHINDEWOLF M,SCHWANER S,WOLTER M,et al.Incidence and causes of heparin-induced skin lesions[J].CMAJ,2009,181(8):477-481.
[16]ROSENBERGER L H,SMITH P W,SAWYER R G.Heparin-induced thrombocytopenia:an increasingly common cause of bilateral adrenal hemorrhage[J].J Am Geriatr Soc,2011,59(6):1157-1158.
[17]SUN L,GIMOTTY P A,LAKSHMANAN S,et al.Diagnostic accuracy of rapid immunoassays for heparin-induced thrombocytopenia:a systematic review and meta-analysis[J].Thromb Haemost,2016,115(5):1044-1055.
[18]WARKENTIN T E.Platelet count monitoring and laboratory testing for heparin-induced thrombocytopenia[J].Arch Pathol Lab Med,2002,126(11):1415-1423.
[19]CUKER A,GIMOTTY P A,CROWTHER M A,et al.Predictive value of the 4Ts scoring system for heparin-induced thrombocytopenia:a systematic review and meta-analysis[J].Blood,2012,120(20):4160-4167.
[20]LINKINS L A,DANS A L,MOORES L K,et al.Treatment and prevention of heparin-induced thrombocytopenia:antithrombotic therapy and prevention of thrombosis,9th ed:American College of Chest Physicians Evidence-Based Clinical Practice Guidelines[J].Chest,2012,141(2 Suppl):e495S-530.
[21]GREINACHER A.Heparin-induced thrombocytopenia[J].N Engl J Med,2015,373(19):1883-1884.
[22]KRAUEL K,HACKBARTH C,FRLL B,et al.Heparin-induced thrombocytopenia:in vitro studies on the interaction of dabigatran,rivaroxaban,and low-sulfated heparin,with platelet factor 4 and anti-PF4/heparin antibodies[J].Blood,2012,119(5):1248-1255. |